PlateletBio Overview
- Year Founded
-
2014
- Status
-
Out of Business
- Employees
-
52
- Latest Deal Type
-
Out of Business
PlateletBio General Information
Description
Developer of a biotechnology allogeneic cell therapy platform designed to provide life-saving human platelets from stem cells for therapeutic applications. The company's platform provides platelets, which are made using its patented microfluidic bioreactor that permits the production of mature blood cells, for transfusion therapy and replaces the need for a human platelet donor, enabling patients to have improved platelet purity to become bacteria and virus-free and produce immune-compatible human platelets to stay healthy.
Contact Information
Website
www.plateletbio.comCorporate Office
- 65 Grove Street
- Suite 303
- Watertown, MA 02472
- United States
Corporate Office
- 65 Grove Street
- Suite 303
- Watertown, MA 02472
- United States
PlateletBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Out of Business | 02-Dec-2023 | Completed | Out of Business | |||
| 13. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 12. Later Stage VC (Series B) | 04-Nov-2021 | Completed | Clinical Trials - General | |||
| 11. Grant | 16-Dec-2019 | Completed | Clinical Trials - General | |||
| 10. Early Stage VC (Series A) | 13-Aug-2019 | Completed | Clinical Trials - General | |||
| 9. Early Stage VC (Series A1) | 31-May-2017 | Completed | Clinical Trials - General | |||
| 8. Grant | 05-Jan-2017 | Completed | Clinical Trials - General | |||
| 7. Seed Round | 28-Jul-2016 | Completed | Clinical Trials - General | |||
| 6. Seed Round | $250K | $250K | Completed | Clinical Trials - General | ||
| 5. Grant | 04-May-2016 | $1.5M | Completed | Clinical Trials - General |
PlateletBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-Plus | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 1,785,881 | $0.000100 | $0.14 | $0.14 | 1x | $0.14 | 1.72% | |
| Series A-1 | 9,742,785 | $0.000100 | $1.03 | $1.03 | 1x | $1.03 | 9.38% |
PlateletBio Patents
PlateletBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021231990-A1 | Improved methods and production of novel platelets | Inactive | 15-May-2020 | ||
| JP-2026016605-A | Anucleated cells as a source for the treatment of platelet-rich plasma-dependent disorders | Pending | 14-May-2020 | ||
| AU-2021273015-A1 | Novel anucleated cells as a source for treatment of platelet rich plasma dependent disorders | Pending | 14-May-2020 | ||
| CA-3178603-A1 | Novel anucleated cells as a source for treatment of platelet rich plasma dependent disorders | Pending | 14-May-2020 | ||
| EP-4149497-A1 | Novel anucleated cells as a source for treatment of platelet rich plasma dependent disorders | Pending | 14-May-2020 | C12N5/0644 |
PlateletBio Signals
PlateletBio FAQs
-
When was PlateletBio founded?
PlateletBio was founded in 2014.
-
Where is PlateletBio headquartered?
PlateletBio is headquartered in Watertown, MA.
-
What is the size of PlateletBio?
PlateletBio has 52 total employees.
-
What industry is PlateletBio in?
PlateletBio’s primary industry is Biotechnology.
-
Is PlateletBio a private or public company?
PlateletBio is a Private company.
-
What is PlateletBio’s current revenue?
The current revenue for PlateletBio is .
-
How much funding has PlateletBio raised over time?
PlateletBio has raised $133M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process